Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaDavid H. Henry, Howard Yeh, Luís Costa et al.|Journal of Clinical Oncology|2011Cited by 1.3k
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumorsDavid H. Henry, Howard Yeh, Saroj Vadhan‐Raj et al.|Supportive Care in Cancer|2013Cited by 182
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristicsAllan Lipton, Ada Braun, David H. Henry et al.|European Journal of Cancer|2015Cited by 114
An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myelomaRavi Vij, Susie Jun, Noemi Horvath et al.|American Journal of Hematology|2009Cited by 97
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemiaSaroj Vadhan‐Raj, Eric Roeland, Rafat Abonour et al.|Journal of Hematology & Oncology|2017Cited by 88